share_log

東陽光長江藥業：中期報告2024

HEC CJ PHARM: Interim Report 2024

HKEX ·  Sep 30 18:01

Summary by Futu AI

宜昌東陽光長江藥業股份有限公司（「東陽光長江藥業」）公佈截至2024年6月30日止六個月的未經審核中期財務報告。報告顯示，公司營業額為人民幣2,454,762千元，較去年同期的人民幣3,209,002千元下降23.5%。毛利為人民幣1,949,232千元，較去年同期的人民幣2,563,937千元下降24%。期內溢利為人民幣684,731千元，較去年同期的人民幣1,023,924千元下降33.1%。每股基本及攤薄盈利均為人民幣0.78元。截至2024年6月30日，公司淨資產為人民幣8,665,380千元。公司董事會決定不派發截至2024年6月30日止六個月的中期股息。公司的主要業務包括抗感染兒科線、慢病線、新藥線及集採和新零售線的藥品銷售。報告期內，公司與其關聯方進行了一系列交易，包括購買貨品、接受服務、租賃資產及銷售貨品等。公司的財務狀況良好，具有充足的現金流和穩健的資本結構。
宜昌東陽光長江藥業股份有限公司（「東陽光長江藥業」）公佈截至2024年6月30日止六個月的未經審核中期財務報告。報告顯示，公司營業額為人民幣2,454,762千元，較去年同期的人民幣3,209,002千元下降23.5%。毛利為人民幣1,949,232千元，較去年同期的人民幣2,563,937千元下降24%。期內溢利為人民幣684,731千元，較去年同期的人民幣1,023,924千元下降33.1%。每股基本及攤薄盈利均為人民幣0.78元。截至2024年6月30日，公司淨資產為人民幣8,665,380千元。公司董事會決定不派發截至2024年6月30日止六個月的中期股息。公司的主要業務包括抗感染兒科線、慢病線、新藥線及集採和新零售線的藥品銷售。報告期內，公司與其關聯方進行了一系列交易，包括購買貨品、接受服務、租賃資產及銷售貨品等。公司的財務狀況良好，具有充足的現金流和穩健的資本結構。
Hec CJ Pharm Co., Ltd. ("Hec CJ Pharm") announced its unaudited interim financial report for the six months ended June 30, 2024. The report shows that the company's revenue was RMB 2,454,762 thousand, a decrease of 23.5% compared to RMB 3,209,002 thousand in the same period last year. The gross profit was RMB 1,949,232 thousand, a decrease of 24% compared to RMB 2,563,937 thousand in the same period last year. The net profit for the period was RMB 684,731 thousand, a decrease of 33.1% compared to RMB 1,023,924 thousand in the same period last year. The basic and diluted earnings per share were both RMB 0.78. As of June 30, 2024, the company's net assets were RMB 8,665,380 thousand. The board of directors decided not to distribute an interim dividend for the six...Show More
Hec CJ Pharm Co., Ltd. ("Hec CJ Pharm") announced its unaudited interim financial report for the six months ended June 30, 2024. The report shows that the company's revenue was RMB 2,454,762 thousand, a decrease of 23.5% compared to RMB 3,209,002 thousand in the same period last year. The gross profit was RMB 1,949,232 thousand, a decrease of 24% compared to RMB 2,563,937 thousand in the same period last year. The net profit for the period was RMB 684,731 thousand, a decrease of 33.1% compared to RMB 1,023,924 thousand in the same period last year. The basic and diluted earnings per share were both RMB 0.78. As of June 30, 2024, the company's net assets were RMB 8,665,380 thousand. The board of directors decided not to distribute an interim dividend for the six months ended June 30, 2024. The company's main business includes the sale of pharmaceutical products in the anti-infection pediatric line, chronic disease line, new drug line, and the centralized procurement and new retail line. During the reporting period, the company conducted a series of trades with its related parties, including purchasing goods, receiving services, leasing assets, and selling goods. The company is in good financial condition with sufficient cash flow and a robust capital structure.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated